Viewing Study NCT02498600

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 12:16 PM
Ignite Modification Date: 2026-02-22 @ 4:10 AM
Study NCT ID: NCT02498600
Status: COMPLETED
Last Update Posted: 2025-08-29
First Post: 2015-07-14
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Recurrent Fallopian Tube Carcinoma View
None Recurrent Ovarian Carcinoma View
None Recurrent Primary Peritoneal Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Phase II Randomized Trial of Nivolumab with or without Ipilimumab … View
None Primary Peritoneal or Fallopian View
None Tube Cancer View